Week In Review: YishengBio To List On Nasdaq Via SPAC Merger At An $834 Million Value

Beijing YishengBio will merge with SPAC vehicle Summit Healthcare Acquisition to list on Nasdaq. Sihuan Pharma subsidiary Xuanzhu Biopharm has filed for an IPO on the Shanghai STAR Exchange.

Related Keywords

Jilin ,China ,Yisheng ,Zhejiang ,Jinan ,Shandong ,Shanghai ,Hong Kong ,Suzhou ,Jiangsu ,Belgium ,Boston ,Massachusetts ,United States ,Beijing ,Nanjing ,Sihuan Pharma ,Xuanzhu Biopharm ,Huisheng Biopharm ,Seattle Seagen ,Kiomed Pharma ,Joan Shen ,Hansoh Pharma ,Sichuan Kelun ,Simcere Pharma ,Nasdaq Exchange ,Zai Lab ,Horae Gene Therapy Center ,Cell Research ,Shanghai Zai Lab ,Umass Chan Medical School ,Summit Healthcare Acquisition ,For Almirall ,Jilin Huisheng Biopharm ,Greater China ,Shen Therapeutics ,Chan Medical School ,Massachusett Creagen Life Science Incubato ,Bioheng Biotech ,Sichuan Kelun Biotech ,